CURB-65
(Redirected from CURB65)
CURB-65 Score[edit | edit source]
CURB-65, also known as the CURB criteria, is a widely-used clinical prediction rule that helps in assessing the severity and mortality risk in patients with community-acquired pneumonia (CAP). Developed in 2002 by Dr. W.S. Lim and colleagues at the University of Nottingham, CURB-65 is an acronym representing each of the risk factors evaluated in the score. It has been endorsed by the British Thoracic Society for pneumonia severity assessment and is instrumental in guiding treatment decisions.
Background and Development[edit | edit source]
The CURB-65 score was developed as an improvement over the earlier CURB score. It was created to provide a simple yet effective tool for quickly assessing the severity of pneumonia in a clinical setting. The aim was to improve patient care by identifying those at higher risk of mortality who may require more intensive treatment or hospitalization.
Components of CURB-65[edit | edit source]
CURB-65 includes five clinical criteria:
- C - Confusion of new onset
- U - Blood Urea nitrogen > 7 mmol/L (19 mg/dL)
- R - Respiratory rate ≥ 30 breaths/min
- B - Blood pressure: Systolic < 90 mm Hg or Diastolic ≤ 60 mm Hg
- 65 - Age ≥ 65 years
Each factor scores one point, with a maximum score of 5.
Clinical Application[edit | edit source]
The CURB-65 score is used primarily to assess the severity of pneumonia and guide treatment decisions. It helps in determining:
- The need for hospitalization or intensive care unit admission
- Appropriate level of care and monitoring required
- Potential for outpatient treatment in less severe cases
Updates and Modifications[edit | edit source]
In 2018, a new toolkit based on CURB-65 was introduced, incorporating additional factors to enhance its predictive accuracy. This includes considerations of comorbid conditions and other clinical indicators.
Validation and Effectiveness[edit | edit source]
Numerous studies have validated the effectiveness of the CURB-65 score in predicting mortality in CAP. It is recognized for its simplicity, ease of use, and clinical utility.
References[edit | edit source]
- Lim, W.S., et al. (2002). "Development of a predictive rule for community-acquired pneumonia." Thorax.
- British Thoracic Society. (2018). "Guidelines for the management of community-acquired pneumonia in adults."
CURB-65 Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Kondreddy Naveen